Abstract
The identification of the BRCA1 and BRCA2 genes has helped move genetics from rare disorders of childhood to common diseases of adulthood. Clinical testing programs are currently thriving, but will need to identify more effective ways to bill for services and how to expand access via the internet or telephone counseling without sacrificing quality. Lastly, the impact of gene patenting will need continued monitoring, because it is crucial that researchers be allowed to continue developing new and better tests to benefit all patients at high risk.
